#VisualAbstract: Risankizumab was Non-Inferior to Ustekinumab for the Clinical Remission of Moderate-to-Severe Crohn’s Disease
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: risankizumab
Risankizumab is superior to ustekinumab for endoscopic remission of Crohn’s disease
1. In this randomized controlled trial, risankizumab was non-inferior to ustekinumab in terms of clinical remission at 24 weeks in ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)
In this randomized controlled trial, 605 patients with moderate-to-severe chronic plaque psoriasis were assigned to receive 150 mg risankizumab subcutaneously ...
2 Minute Medicine Rewind July 8, 2019
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised ...